Glenmark Pharmaceuticals announced that Glenmark Pharmaceuticals Europe has entered into a strategic, exclusive licensing agreement for marketing generic Tiotropium Bromide dry powder inhaler (DPI) in Western Europe.
Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim's Spiriva Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD).
This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler.
According to data from IQVIA, Boehringer Ingelheim's Spiriva Handihaler recorded sales of USD 724 million in the EU in the 12 month period ended March 2018.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
